Compare Stocks: IVA, OGN, GPCR, and TARS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$47.34	$50.77	$19.50 ▼ $94.90	$3.30B	-1.45	721,795 shs	253,397 shs
IVA Inventiva	$4.78 -1.2%	$4.51	$3.35 ▼ $7.98	$992.84M	0.71	672,315 shs	1.35 million shs
OGN Organon & Co.	$13.78 +0.1%	$13.61	$5.69 ▼ $13.78	$3.62B	1.52	3.21 million shs	4.87 million shs
TARS Tarsus Pharmaceuticals	$90.78 +9.1%	$66.01	$48.20 ▼ $91.53	$3.98B	0.54	743,029 shs	1.60 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	0.00%	-0.06%	-10.03%	+25.97%	+140.18%
IVA Inventiva	0.00%	+1.70%	+2.58%	+18.61%	-17.16%
OGN Organon & Co.	0.00%	+0.07%	+1.66%	+2.87%	+40.55%
TARS Tarsus Pharmaceuticals	0.00%	+26.51%	+38.96%	+53.14%	+57.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GPCR Structure Therapeutics	$47.34	$50.77	$19.50 ▼ $94.90	$3.30B	-1.45	721,795 shs	253,397 shs
IVA Inventiva	$4.78 -1.2%	$4.51	$3.35 ▼ $7.98	$992.84M	0.71	672,315 shs	1.35 million shs
OGN Organon & Co.	$13.78 +0.1%	$13.61	$5.69 ▼ $13.78	$3.62B	1.52	3.21 million shs	4.87 million shs
TARS Tarsus Pharmaceuticals	$90.78 +9.1%	$66.01	$48.20 ▼ $91.53	$3.98B	0.54	743,029 shs	1.60 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GPCR Structure Therapeutics	0.00%	-0.06%	-10.03%	+25.97%	+140.18%
IVA Inventiva	0.00%	+1.70%	+2.58%	+18.61%	-17.16%
OGN Organon & Co.	0.00%	+0.07%	+1.66%	+2.87%	+40.55%
TARS Tarsus Pharmaceuticals	0.00%	+26.51%	+38.96%	+53.14%	+57.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GPCR Structure Therapeutics	2.89	Moderate Buy	$110.91	134.28% Upside
IVA Inventiva	3.10	Buy	$15.38	221.65% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-17.27% Downside
TARS Tarsus Pharmaceuticals	2.90	Moderate Buy	$90.50	-0.31% Downside

Current Analyst Ratings Breakdown

Latest IVA, OGN, GPCR, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/12/2026	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$97.00 ➝ $100.00
8/7/2026	GPCR Structure Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$111.00
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/7/2026	GPCR Structure Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$100.00 ➝ $97.00
8/7/2026	GPCR Structure Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$113.00 ➝ $110.00
8/3/2026	OGN Organon & Co.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/31/2026	TARS Tarsus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$100.00 ➝ $98.00
7/21/2026	TARS Tarsus Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$90.00 ➝ $89.00
7/17/2026	GPCR Structure Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IVA Inventiva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$19.45 per share	N/A
IVA Inventiva	$5.07M	195.83	N/A	N/A	($0.22) per share	-21.73
OGN Organon & Co.	$6.22B	0.58	$5.79 per share	2.38	$3.83 per share	3.60
TARS Tarsus Pharmaceuticals	$451.36M	8.83	N/A	N/A	$7.90 per share	11.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GPCR Structure Therapeutics	-$141.20M	-$1.00	N/A	N/A	N/A	N/A	-25.56%	-24.31%	11/5/2026 (Estimated)
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.90	4.01	1.28	3.41%	88.97%	6.03%	11/9/2026 (Estimated)
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	159.26	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)

Latest IVA, OGN, GPCR, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2026	Q2 2026	IVA Inventiva	-$0.20	N/A	N/A	N/A	$6.35 million	N/A
8/6/2026	Q2 2026	GPCR Structure Therapeutics	-$0.39	-$0.49	-$0.10	-$0.49	N/A	N/A
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.58%	N/A	10.39%	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest IVA, OGN, GPCR, and TARS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.58%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GPCR Structure Therapeutics	N/A	20.75	20.75
IVA Inventiva	N/A	3.16	3.16
OGN Organon & Co.	8.43	1.95	1.44
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GPCR Structure Therapeutics	91.78%
IVA Inventiva	19.06%
OGN Organon & Co.	77.43%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
GPCR Structure Therapeutics	5.50%
IVA Inventiva	32.00%
OGN Organon & Co.	1.62%
TARS Tarsus Pharmaceuticals	9.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GPCR Structure Therapeutics	136	69.62 million	65.79 million	Optionable
IVA Inventiva	100	207.71 million	141.24 million	Not Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable

IVA, OGN, GPCR, and TARS Headlines

Recent News About These Companies

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Upgraded by Jefferies Financial Group

September 5 at 7:59 AM | marketbeat.com

Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition

September 4 at 8:35 PM | marketscreener.comM

Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals

September 4 at 3:35 PM | finance.yahoo.com

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

September 4 at 3:35 PM | rttnews.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week High - Should You Buy?

September 4 at 2:19 PM | marketbeat.com

Tarsus Pharmaceuticals Completes Acquisition of Alkeus, Adds Gildeuretinol for Stargardt Disease to Pipeline

September 4 at 8:51 AM | quiverquant.comQ

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

September 4 at 8:38 AM | globenewswire.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $339,829.86 in Stock

September 4 at 6:52 AM | insidertrades.com

114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp

September 4 at 3:20 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 4,601 Shares of Stock

September 3 at 5:07 PM | marketbeat.com

Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 5,387 Shares

September 3 at 5:07 PM | marketbeat.com

Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease

September 3 at 11:10 AM | globenewswire.com

The Manufacturers Life Insurance Company Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

September 3 at 4:32 AM | marketbeat.com

Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 6.5% Higher - Should You Buy?

September 2, 2026 | marketbeat.com

Tarsus to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Hsbc Holdings PLC Makes New $2.43 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

August 31, 2026 | marketbeat.com

Canada Pension Plan Investment Board Acquires Shares of 98,900 Tarsus Pharmaceuticals, Inc. $TARS

August 31, 2026 | marketbeat.com

Freestone Grove Partners LP Takes Position in Tarsus Pharmaceuticals, Inc. $TARS

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Acquires New Position in Tarsus Pharmaceuticals, Inc. $TARS

August 28, 2026 | marketbeat.com

90,969 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Connor Clark & Lunn Investment Management Ltd.

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $7.91 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS

August 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IVA, OGN, GPCR, and TARS Company Descriptions

Structure Therapeutics NASDAQ:GPCR

$47.34 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Inventiva NASDAQ:IVA

$4.78 -0.06 (-1.24%)

As of 09/4/2026 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Organon & Co. NYSE:OGN

$13.78 +0.01 (+0.07%)

As of 09/4/2026 03:58 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Tarsus Pharmaceuticals NASDAQ:TARS

$90.78 +7.57 (+9.10%)

As of 09/4/2026 04:00 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVA, OGN, GPCR, and TARS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVA, OGN, GPCR, and TARS Earnings

Compare Dividends

Latest IVA, OGN, GPCR, and TARS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVA, OGN, GPCR, and TARS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IVA, OGN, GPCR, and TARS Company Descriptions

Structure Therapeutics NASDAQ:GPCR

Inventiva NASDAQ:IVA

Organon & Co. NYSE:OGN

Tarsus Pharmaceuticals NASDAQ:TARS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools